Skip to main content

Company News



  • AstraZeneca Pharma receives permission for Palivizumab admin Mon, 10/02/2023 - 15:47

    AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Palivizumab (Synagis) solution for injection 100 mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL presentations in single-dose vials administered through intramuscular route).

  • Johnson & Johnson offers USD 8.9 Bn to settle talc suits

    Johnson & Johnson has reached a deal in the long-running lawsuit against its talc-based products. Thousands of people have sued the company over the past decade, claiming the products - including its iconic baby powder - caused cancer.

  • Granules Consumer Health Inc., inaugurates its Packaging Facility in the U.S.

    Granules India inaugurated and launched its packaging facility through its Granules Consumer Health (GCH) step-down subsidiary which is located in Manassas, Virginia, US. The facility is over 79,000 square feet and is equipped with packaging lines and clean rooms to package and ship prescription and over-the-counter products across the U.S. market. The facility recently received US FDA approval with zero 483 observations.

  • Granules India Limited Received ANDA approval for Losartan Potassium Tablets

    Granules India Limited announced that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg.

    It is bioequivalent to the reference listed drug product (RLD), Cozaar Tablets of Organon LLC. Granules now has a total of 54 ANDA approvals from US FDA (52 Final approvals and 2 tentative approvals).

  • For the first time, Sun Pharma outperforms Mankind in prescription

    For the first time Sun Pharma secured the top position by doctor prescriptions. It outperforms Mankind Pharma long stand, according to market research firm, SMSRC.

    Sun Pharma is the largest Indian pharma company by capital, but Mankind Pharma was leading market rank for number of doctor prescriptions for a long time. Recently as per market research firm, SMSRC, Sun Pharma, which has topped India’s pharma retail market for years, has now become the leader in prescriptions, bolstered by an increase in field force and a sharper focus on core therapies.

  • BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing

    BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART  leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.

  • Bharat Biotech joined with Biofabri to develop and distribute novel TB vaccine

    Bharat Biotech has entered into a partnership with Biofabri, a Spanish biopharmaceutical firm, for the development, manufacturing and marketing of a new tuberculosis vaccine. This partnership will guarantee the supply of TB vaccines in more than 70 countries especially in Southeast Asia, and sub-Saharan Africa with a high TB incidence.

  • Kumar Organic Products adjudged as BEST INNOVATIVE COMPANY

    The world economy is seeing its greatest fall ever. Coronavirus has largely impacted the growth of almost every country and is responsible for the slump in GDP worldwide. Like other countries, India is also impacted by this virus too. Almost every industry sector has seen a fall in their sales and revenue. India’s GDP growth has fallen to 4.7% in the third quarter of 2020.

  • Roche announced that the UFDA has granted Emergency Use Authorization for its COVID-19 at Home Test

    Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its COVID-19 At-Home Test. The test uses a simple anterior nasal swab sample that can be conveniently self-collected and self-tested by individuals aged 14 years and older, and by an adult for children aged 2-13 years old. The test is able to produce accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.

  • Merck pill receives U.S. FDA EUA for COVID-19

    Merck announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for molnupiravir, an investigational oral antiviral (MK-4482, EIDD-2801).

Subscribe to Company News